{"id":"W2618328561","doi":"10.1182/blood.v128.22.4497.4497","title":"Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University Health Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Progressive disease; Internal medicine; Regimen; Multiple myeloma; Neutropenia; Population; Phases of clinical research; Clinical endpoint; Dexamethasone; Oncology; Surgery; Gastroenterology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901254,0.001668865,0.002162584,0.0005684458,0.0003724477,0.001333526,0.00109384,0.001140495,0.00450909],"category_scores_gemma":[0.00108338,0.0006826213,0.001960482,0.000546688,0.0007547706,0.0008988091,0.0004961329,0.003402643,0.0008308862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001265282,"about_ca_system_score_gemma":0.001729009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008876608,"about_ca_topic_score_gemma":0.002299496,"domain_scores_codex":[0.9994276,0.0002621069,0.00003947046,0.0001217183,0.00007019602,0.00007900242],"domain_scores_gemma":[0.9992898,0.0001039109,0.0001942835,0.00006237443,0.00004323032,0.000306381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7659344,0.1192375,0.006846352,0.001180762,0.002931396,0.0002969881,0.0002253221,0.001502116,0.0222907,0.0001833881,0.002380294,0.07699082],"study_design_scores_gemma":[0.5328987,0.4498225,0.01044176,0.00005526702,0.001183755,0.0003449041,0.00005398461,0.0006880894,0.00211105,0.0001357512,0.0022308,0.00003350478],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903955,0.003353645,0.0003750013,0.0002912811,0.0001156525,0.002922536,0.001259095,0.00006846621,0.001218821],"genre_scores_gemma":[0.9866285,0.003002906,0.001470921,0.0009985074,0.0002678637,0.002838513,0.002625668,0.00002486104,0.002142326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00450909,"threshold_uncertainty_score":0.01508439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05209713618252999,"score_gpt":0.343318897946253,"score_spread":0.2912217617637231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}